Industry Cites Excess Burden, Lack of Guidance in Proposed Combo GMP Rule

Drug Industry Daily
Combination-product stakeholders suggest that the FDA’s proposed rule on good manufacturing practices (GMPs) for those products add postapproval change control guidance, simplify other requirements and extend the waiting period for the rule to take effect.

To View This Article:


Subscribe To Drug Industry Daily